SOAT1 and glomerular disorder: Finally, while growing evidence demonstrates that a pharmacological block of the JAK-STAT pathway could effectively treat nephropathy, for decades, the first-line treatment for obesity-related glomerulopathy has been RAS inhibitors (Jiang et al., 2023).